ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening ...

Earlier this week, Labcorp announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered for eligible Medicare and Medicare ...

Regular preventive screenings can make a life-changing difference—especially when it comes to cancer. According to the American Cancer Society, colorectal cancer is the third-leading cause of ...

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical ...

FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Labcorp has announced the availability of ColoSense, its ribonucleic acid (RNA)-based at-home screening test for colorectal cancer that has been approved by the US Food and Drug Administration (FDA).

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...